Clinical trial
Darbepoetin Alpha in Myelodysplastic Syndromes (MDS)
NCT00443339 · Groupe Francophone des Myelodysplasies, Other · Unknown status
Key facts
| NCT number | NCT00443339 |
|---|---|
| Title | Darbepoetin Alpha in Myelodysplastic Syndromes (MDS) |
| Official title | A Phase II Study of Darbepoetin Alpha in Myelodysplastic Syndromes (MSD) |
| Lead sponsor | Groupe Francophone des Myelodysplasies, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | Darbepoetin |
| Enrollment | 99 |
| Start date | Dec 1, 2006 |
| Completion | Jul 1, 2008 |
| First posted | Mar 6, 2007 |
| Last update posted | May 17, 2007 |
| Countries | France |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: